Patents Assigned to INSERM, Institut National de la Sante et de la Recherche Medicale
  • Patent number: 11371061
    Abstract: The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 28, 2022
    Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY VAL D'ESSONNE
    Inventors: Saliha Majdoul, David Fenard
  • Patent number: 11365257
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: June 21, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICS
    Inventors: Elise Chiffoleau, Géraldine Teppaz, Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
  • Patent number: 11365392
    Abstract: The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4+ Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCR??+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCR??+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 21, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), MEDECINE ET INNOVATION, UNIVERSITÉ PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Zagury, Helene Le Buanec, Sophie Duchez, Valerie Schiavon, Armand Bensussan
  • Patent number: 11365251
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: June 21, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de Strasbourg
    Inventors: Thomas Baumert, Rajeevkumar Tawar
  • Patent number: 11352372
    Abstract: The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea atopic dermatitis, psoriasis and itch) caused by abnormally high levels of protease activity (particularly of serine proteases such as kallikreins). In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: June 7, 2022
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: John Liddle, Ann Louise Walker, Gemma Victoria White, Alexis Denis, Nerina Dodic, Marie-Hélène Fouchet, Anne Bouillot
  • Patent number: 11351226
    Abstract: Cytoablative treatments lead to severe damages on thymic epithelial cells (TECs), which result in delayed de novo thymopoïesis and a prolonged period of T-cell immunodeficiency. Understanding the mechanisms that govern thymic regeneration is of paramount interest for the recovery of a functional immune system notably after bone marrow transplantation (BMT). Here, the inventors show that administration of RANK ligand (RANKL) after total body irradiation and BMT boosts thymic regeneration. Notably, this treatment is also beneficial upon BMT in aged individuals. The inventors show that RANKL can improve thymopoiesis in aged individuals affected by thymic involution. Finally, the inventors show that RANK receptor is conserved in the human thymus. Accordingly, one aspect of the present invention relates to a method of boosting thymic regeneration in a patient suffering from a thymic injury comprising administering to the subject a therapeutically effective amount of a RANKL polypeptide.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 7, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Magali Irla, Noella Lopes
  • Publication number: 20220160716
    Abstract: A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases. A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 26, 2022
    Applicants: SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), MANROS THERAPEUTICS
    Inventors: Thomas FALGUIERES, Virginie VAUTHIER, Laurent MEIJER, Nassima OUMATA
  • Patent number: 11339406
    Abstract: The present invention relates to variants of acid-alpha glucosidase and uses thereof.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: May 24, 2022
    Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY VAL D'ESSONNE
    Inventors: Federico Mingozzi, Giuseppe Ronzitti
  • Patent number: 11318113
    Abstract: The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: May 3, 2022
    Assignees: OP2 DRUGS, CENTRE HOSPITALIER UNIVERSITAIRE DE BOURDEAUX, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE BORDEAUX
    Inventors: Philippe Diolez, Dominique Detaille, Frédéric Marin, Olivier Petitjean
  • Patent number: 11319352
    Abstract: Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: May 3, 2022
    Assignees: TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
    Inventors: Serguei Fetissov, Grégory Lambert, Romain Legrand, Nicolas Lucas
  • Patent number: 11311484
    Abstract: The present invention relates to a method for treating skin afflictions in a subject comprising a step of administering said subject with a therapeutically effective amount of small extracellular vesicles (sEV) comprising CD98hc. Inventors have demonstrated that healthy dermal fibroblasts produced and secreted EVs bearing characteristic of exosome-like small EVs (sEVs). They have shown that CD98hc was present at the surface of sEVs, transferred and stabilized at the plasma membrane of recipient cells. They observed that the transferred protein was functional both in vitro and in vivo. Furthermore, injection of sEVs in epidermal CD98hc KO mice exhibiting wound healing defect rescued wound closure in vivo. Thus, their findings reveal that CD98hc contained in EVs could potentially be used in vivo to treat and improve multiple skin afflictions by allowing protein rescue.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: April 26, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Nice Sophia Antipolis, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Chloé Feral, Floriane Tissot, Laurence Cailleteau, Soline Estrach
  • Patent number: 11306294
    Abstract: The invention relates to a virus-like particle comprising an autoantigen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an autoimmune disease.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 19, 2022
    Assignees: Sorbonne Universite, INSERM (Institut National De La Sante Et De La Recherche Medicale), Assistance Publique—Hopitaux De Paris
    Inventors: Bertrand Bellier, David Klatzmann
  • Patent number: 11298348
    Abstract: Sarcoglycanopathies are autosomal recessive diseases caused by mutations in the one of the genes coding for any sarcoglycans (SG). The inventors previously showed that the application of small molecules developed to rescue ?F508-CFTR trafficking, and known as CFTR correctors, improved the maturation of several ?-sarcoglycan mutants that were consequently rescued at the plasma membrane (WO 014086687). Now, the inventors show that some specific CFTR correctors provide additive and even synergic effect when administered in combination.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: April 12, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE), UNIVERSITE D'EVRY-VAL-D'ESSONNE, GENETHON, UNIVERSITA 'DEGLI STUDI DI PADOVA
    Inventors: Isabelle Richard, Dorianna Sandona
  • Patent number: 11300568
    Abstract: The present invention relates to the diagnosis of gastrointestinal stromal tumors (GISTs). The present invention also relates to methods and compositions for the treatment of gastrointestinal stromal tumors (GISTs).
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 12, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pascal De Santa Barbara, Sandrine Faure-De Santa Barbara
  • Publication number: 20220096452
    Abstract: A local anesthetic chosen from the group of amino amide or amino ester, and a composition or pharmaceutical composition including the local anesthetic. The local anesthetic is for use in the treatment of neurological symptoms resulting from brain dysfunctions such as motor, cognitive, sensory, visual deficits, and/or apathetic, catatonic, vegetative and/or minimally conscious states.
    Type: Application
    Filed: January 22, 2020
    Publication date: March 31, 2022
    Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE
    Inventors: Laurent COHEN, Randa EL HACHEM, Piirika CREPIN, Guillaume GUERINEAU DE LAMERIE, Gérard SYLVESTRE
  • Publication number: 20220098264
    Abstract: Interleukin-34 is a cytokine that is involved in the differentiation and survival of macrophages, monocytes, and dendritic cells in response to inflammation. The involvement of IL-34 has been shown in areas as diverse as neuronal protection, autoimmune diseases, infection, cancer, and transplantation. Recent work has also demonstrated a new and possible therapeutic role for IL-34 as a Foxp3+ Treg-secreted cytokine mediator of transplant tolerance. New mutated IL-34 polypeptides have been generated, which can be used as agonists or antagonists.
    Type: Application
    Filed: January 15, 2020
    Publication date: March 31, 2022
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE NANTES
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON, Erwan MORTIER, Agnès QUEMENER
  • Patent number: 11285180
    Abstract: The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal models, the inventors identified that a specific gut microbiota signature impairs GLP-1-activated gut-brain axis which could be transferred to germ free mice. The dysbiotic gut microbiota induces enteric neuropathy, reduces GLP-1 receptor and nNOS mRNA concentration, GLP-1-induced nitric oxide production for the control of insulin secretion and gastric emptying. The frequency of Lactobacilli in the ileum microbiota was tightly correlated with nMOS mRNA concentration, which is a mode of action of GLP-1, of the enteric nervous system opening a novel route for the improvement of GLP-1 based therapies in type 2 diabetic patients. In particular, the present invention relates to a method of enhancing the potency of an incretin-based drug administered to a diabetic subject as part of a treatment regimen.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: March 29, 2022
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Université Paul Sabatier Toulouse III
    Inventors: Remy Burcelin, Francois Terce, Estelle Grasset, Jeffrey Christensen, Xavier Collet
  • Publication number: 20220079507
    Abstract: A system to measure and monitor neurodegeneration of a subject, which includes: an acquisition module configured to acquire electroencephalographic signals with multiple EEG channels from a subject perceptually isolated; a calculation module configured to extract at least one EEG metric representative of neurodegeneration; and an evaluation module configured to evaluate the at least one EEG metric and extract a neurodegeneration index.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 17, 2022
    Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITÉ
    Inventors: Stephane EPELBAUM, Sinead GAUBERT, Federico RAIMONDO, Jacobo D SITT, Lionel NACCACHE
  • Patent number: 11274160
    Abstract: The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed in several cancers and notably in 30%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, which are tumors of bad prognosis. Treatments remain still elusive. That's why the inventors developed a new targeted therapy based on an antibody having specificity to nectin-4 (called 14A5.2 mab). Indeed, the inventors selected this antibody for its intrinsic prophylactic anti-metastatic properties and also for the treatment of localized primary and metastatic cancer. More, the 14A5.2 mab could be indicated for the treatment of cancer resistant to ASG-22ME (from Astellas company). Thus, the invention relates to the 14A5.2 mab and its uses thereof.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: March 15, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, INSTITUT JEAN PAOLI & IRENE CALETTES, CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE
    Inventor: Marc Lopez
  • Patent number: 11272880
    Abstract: Disclosed is a device suitable for measuring the brain activity signals of an individual, the device being intended to be placed on the head of the individual and having a structure intended to carry sensors, the structure allowing the position of the sensors to be adjusted. The structure of the device has: a deformable central support, which is able to adapt to the curvature of the head and is intended to be positioned along the head, preferably on the median plane of the cranium; flexible guides, which extend laterally with respect to the central support and are spaced apart from each other; sensor supports, which are rigidly connected and fixed to the flexible guides, in adjustable positions along the flexible guides; and a system for tightening the flexible guides.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: March 15, 2022
    Assignees: CENTRE HOSPITALIER UNIVERSITAIRE, UNIVERSITE AMIENS PICARDIE JULES VERNE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ETABLISSEMENTS MALTERRE SARL
    Inventors: Fabrice Wallois, Mahdi Mahmoudzadeh, Reinhard Grebe, Laurent Malterre, Javad Safaie